title: [Combined intravitreal therapy for age-related macular disease].
abstract: Since the introduction of anti-VEGF drugs for the treatmet of CNV in age-related macular degeneration (AMD), visual acuity can be stabilised or improved in a significant number of patients. There is an ongoing debate on the safety, efficiency and economic aspects related to current intravitreal therapeutic concepts. Twenty-four to 36 hours after 80 % low-fluence verteporfin photodynamic therapy (PDT) a combined phrarmacosurgical intravitreal therapy for 52 patients with wet AMD was conducted (multiple therapy). By performing a 23-gauge core vitrectomy with the Intrector, an intravitreal substitution with BSS, dexamethasone and bevacizumab was achieved via a self-adapting two-channel cannula for aspiration and injection in one probe tip. After 14 months the mean gain in visual acuity (VA) was 0.18 Snellen lines, with VA stabilisation in 14 / 52 (27 %) and VA gain in 38 / 52 (73 %) of the patients. This safe pharmacosurgical regimen indicated a low intravitreal retreatment rate of (13 / 52) 25 %.
authors.affiliation: Augenklinik - Abteilung für Netzhaut und Glaskörperchirurgie, Klinikum der Johann Wolfgang Goethe Universität Frankfurt/Main. fkoch1@mac1.com
authors.forename: F
authors.initials: F
authors.lastname: Koch
authors.forename: S
authors.initials: S
authors.lastname: Scholtz
authors.forename: P
authors.initials: P
authors.lastname: Singh
authors.forename: M J
authors.initials: MJ
authors.lastname: Koss
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D006801:Humans; D008268:Macular Degeneration / Q000628:therapy*; D010778:Photochemotherapy / Q000639:trends*; D013256:Steroids / Q000008:administration & dosage*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D013256:Steroids; D042461:Vascular Endothelial Growth Factor A